Vector Science and Therapeutics (TSXV: PAIN) has entered a collaboration with the Andrews Research & Education Foundation (AREF) to clinically evaluate pharma-grade peptides for sports and regenerative medicine. The partnership aims to establish evidence-based standards for musculoskeletal applications, with joint ownership of intellectual property and Vector leading commercialization efforts.
Vector (TSXV: PAIN) announced on Nov. 18, 2026 a collaboration with the Andrews Research & Education Foundation to clinically evaluate pharma-grade peptides for sports and regenerative medicine, with joint IP ownership and Vector leading commercialization. The involvement of Dr. James Andrews and Tommy Thompson may lift the stock near term, but no financial terms, revenues, or order values are disclosed, so the effect is reputational rather than a quantified outlook change.
- • Livestreamed media briefing with Dr. James Andrews and Tommy Thompson at 11 a.m. CST on Nov. 18, 2026
- • Joint ownership of intellectual property from the collaboration, with Vector leading commercialization
- • No financial terms, contract value, or revenue figures are stated in the announcement
- • Clinical programs are only being designed and initiated, so commercial products are not near-term